Gianluca Del Conte
Overview
Explore the profile of Gianluca Del Conte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamilton E, Galsky M, Ochsenreither S, Del Conte G, Martin M, De Miguel M, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5548-5558.
PMID: 39405343
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC). Patients And Methods: Part 1...
2.
Dalla Volta A, Valcamonico F, Zivi A, Procopio G, Sepe P, Del Conte G, et al.
Eur Urol
. 2024 May;
86(3):268-271.
PMID: 38772788
No abstract available.
3.
Santoro A, Assenat E, Yau T, Delord J, Maur M, Knox J, et al.
JHEP Rep
. 2024 Apr;
6(4):101021.
PMID: 38617599
Background & Aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible...
4.
Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, et al.
Neurooncol Adv
. 2022 Nov;
4(1):vdac146.
PMID: 36382109
Background: Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. Trotabresib,...
5.
Filaci G, Fenoglio D, Nole F, Zanardi E, Tomasello L, Aglietta M, et al.
Cancer Immunol Immunother
. 2021 Aug;
70(12):3679-3692.
PMID: 34351436
Debate is around the optimal immunization regimen for cancer vaccines since too intense vaccination schedules may exhaust reactive lymphocytes. GX301 is a telomerase-based cancer vaccine whose safety and immunological effects...
6.
Trevisani F, Di Marco F, Capitanio U, Larcher A, Bettiga A, Dosio F, et al.
Kidney Blood Press Res
. 2020 Jan;
45(2):166-179.
PMID: 31982867
Introduction: An accurate assessment of renal function is needed in the majority of clinical settings. Unfortunately, the most used estimated glomerular filtration rate (eGFR) formulas are affected by significant errors...
7.
Wainberg Z, Alsina M, Soares H, Brana I, Britten C, Del Conte G, et al.
Target Oncol
. 2017 Oct;
12(6):775-785.
PMID: 29067643
Background: This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm...
8.
Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, et al.
BMC Cancer
. 2017 Jul;
17(1):493.
PMID: 28724419
Background: Vinflunine is the only chemotherapeutic agent shown to improve survival in platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium (TCCU) in a phase III clinical trial, which...
9.
Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, et al.
J Clin Oncol
. 2015 May;
33(19):2158-65.
PMID: 26014300
Purpose: We conducted a comprehensive review of the design, implementation, and outcome of first-in-human (FIH) trials of monoclonal antibodies (mAbs) to clearly determine early clinical development strategies for this class...
10.
Moreno Garcia V, Olmos D, Gomez-Roca C, Cassier P, Morales-Barrera R, Del Conte G, et al.
Clin Cancer Res
. 2014 Sep;
20(22):5663-71.
PMID: 25252757
Introduction: Because a dose-response relationship is characteristic of conventional chemotherapy, this concept is widely used for the development of novel cytotoxic (CTX) drugs. However, the need to reach the MTD...